Clinical trial

Phase III COLLECT study – patient recruitment is completed

A placebo-controlled, double-blind, randomized, study to assess the efficacy and safety of Kappaproct® as an add-on to current practice in chronic active treatment refractory UC patients.

Study size
120 subjects randomized.

Countries
Czech Republic, France, Germany, Hungary, Italy, Poland and UK.

Dosing regime
Two doses of 30 mg 4 weeks apart.

Primary Objective
Clinical remission at week 12.

Secondary Objectives
Time to / rate of colectomy and safety / tolerability during 12 months

For additional details about the study, please visit clinicaltrials.gov.